有机化学 ›› 2022, Vol. 42 ›› Issue (2): 557-572.DOI: 10.6023/cjoc202107050 上一篇    下一篇

研究论文

新型泰乐菌素衍生物的设计合成和活性评价

王焕焕a,b, 杨璞a,b, 翟洪进a,b, 张烁a,b, 曹亚权a,b, 杨莹雪a,b, 吴春丽a,b,c,*()   

  1. a 郑州大学药学院 郑州 450001
    b 新药创制与药物安全性评价河南省协同创新中心 郑州 450001
    c 教育部药物制备关键技术重点实验室 郑州 450001
  • 收稿日期:2021-07-24 修回日期:2021-08-29 发布日期:2022-02-24
  • 通讯作者: 吴春丽
  • 基金资助:
    国家重点研究开发(2017YFD0501400)

Design, Synthesis and Activity Evaluation of New Tylosin Derivatives

Huanhuan Wanga,b, Pu Yanga,b, Hongjin Zhaia,b, Shuo Zhanga,b, Yaquan Caoa,b, Yingxue Yanga,b, Chunli Wua,b,c()   

  1. a School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001
    b Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou 450001
    c Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou 450001
  • Received:2021-07-24 Revised:2021-08-29 Published:2022-02-24
  • Contact: Chunli Wu
  • Supported by:
    National Key Research and Development Project of China(2017YFD0501400)

泰乐菌素作为16元大环内酯类抗生素的重要成员之一, 被广泛用于治疗由革兰氏阳性菌和支原体引起的感染性疾病, 对革兰氏阴性菌和耐药菌引起的感染性疾病没有明显治疗效果. 目前扩大泰乐菌素的抗菌谱是对其进行结构改造的目的之一. 以泰乐菌素以及其水解产物脱碳霉糖泰乐菌素(Desmycosin)和5-O-碳霉胺糖泰乐内酯(OMT)为母核, 对其C-20位修饰改造, 并引入含3-喹啉或3-吡啶的侧链, 设计合成了18个新型泰乐菌素半合成衍生物. 目标化合物均经核磁共振氢谱(1H NMR)、核磁共振碳谱(13C NMR)和高分辨质谱仪(HRMS)进行了结构确证. 体外抗敏感菌活性表明, 化合物20-脱氧-20-{N-对氟苄基-N-[1-(3-喹啉基)-1H-1,2,3-三唑-4-基]甲氨基}-5-O-碳霉胺糖基泰乐内酯(4g)表现最为突出, 化合物4g对金黄色葡萄球菌和大肠杆菌的最小抑菌浓度(MIC)为<0.0625和4 μg•mL–1; 体外抗耐药菌活性表明, 化合物4g对溶血性葡萄球菌和大肠杆菌的最小抑菌浓度分别为<0.0625和8 μg•mL–1. 这为进一步结构优化和发现抗菌谱更广、抗菌活性更高的新型泰乐菌素衍生物提供了理论依据.

关键词: 泰乐菌素衍生物, 5-O-碳霉胺糖泰乐内酯, 3-喹啉, 合成, 抗菌活性

Tylosin, as one of the important members of 16 membered macrolide antibiotics, has been widely used in the treatment of infectious diseases caused by gram-positive bacteria and mycoplasma, but has little therapeutic effect on infectious diseases caused by gram-negative bacteria and drug-resistant bacteria. At present, one of the purposes modifying tylosin is to expand its antibacterial spectrum. In this paper, using tylosin and its hydrolysate decarbomycin tylosin (desmycosin) and 5-O-mycaminosyltylonolide (OMT) as mother nucleus, 18 new tylosin semisynthetic derivatives were designed and synthesized by modifying the C-20 position, introducing side chain containing 3-quinoline or 3-pyridine, and then their antibacterial activities were evaluated. The target compounds were confirmed by 1H NMR, 13C NMR and HRMS. The in vitro anti-sensitive bacteria activity showed that 20-deoxy-20-(N-p-fluorobenzyl-N-(1-(3-quinolyl)-1H-1,2,3-triazol-4-yl)methylamino)-5-O-my- caminosyltylonolide (4g) performed the most prominently. Minimum inhibitory concentration (MIC) values of compound 4g against S. aureus and E. coli were < 0.0625 and 4 μg•mL–1. The in vitro anti-drug resistant bacteria activity showed that MIC values of compound 4g against S. hemolyticus and E. coli were < 0.0625 and 8 μg•mL–1. This provides a theoretical basis for further structural optimization and discovery of novel tylosin derivatives with wider antibacterial spectrum and better antibacterial activity.

Key words: tylosin derivatives, 5-O-mycaminosyltylonolide, 3-quinoline, synthesis, antibacterial activity